66 related articles for article (PubMed ID: 28656237)
21. Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review.
Zheng SY; Shen W; Peng YM; Cui HJ; Duan H; Qiu YQ; Li Q; Zhang JY; Sun CY; Zhang X
Medicine (Baltimore); 2018 Nov; 97(48):e13088. PubMed ID: 30508887
[TBL] [Abstract][Full Text] [Related]
22. Matrine induces senescence of human glioblastoma cells through suppression of the IGF1/PI3K/AKT/p27 signaling pathway.
Zhou W; Wang J; Qi Q; Feng Z; Huang B; Chen A; Zhang D; Li W; Zhang Q; Bjerkvig R; Li X; Wang J
Cancer Med; 2018 Sep; 7(9):4729-4743. PubMed ID: 30079478
[TBL] [Abstract][Full Text] [Related]
23. Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer.
Cui X; Jing X; Yi Q; Long C; Tan B; Li X; Chen X; Huang Y; Xiang Z; Tian J; Zhu J
Oncotarget; 2018 Jan; 9(3):3198-3213. PubMed ID: 29423040
[TBL] [Abstract][Full Text] [Related]
24. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Hirsh V
BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
[TBL] [Abstract][Full Text] [Related]
25. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Engle JA; Kolesar JM
Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
[TBL] [Abstract][Full Text] [Related]
26. Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL‑6/JAK1/STAT3 signaling pathway.
Chen SF; Zhang ZY; Zhang JL
Mol Med Rep; 2017 Sep; 16(3):2733-2739. PubMed ID: 28656237
[TBL] [Abstract][Full Text] [Related]
27. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
28. Matrine suppresses proliferation and induces apoptosis in human cholangiocarcinoma cells through suppression of JAK2/STAT3 signaling.
Yang N; Han F; Cui H; Huang J; Wang T; Zhou Y; Zhou J
Pharmacol Rep; 2015 Apr; 67(2):388-93. PubMed ID: 25712669
[TBL] [Abstract][Full Text] [Related]
29. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L
Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037
[TBL] [Abstract][Full Text] [Related]
30. Matrine suppresses cell growth of human chronic myeloid leukemia cells via its inhibition of the interleukin-6/Janus activated kinase/signal transducer and activator of transcription 3 signaling cohort.
Ma L; Zhu Z; Jiang L; Sun X; Lu X; Zhou M; Qian S; Jianyong L
Leuk Lymphoma; 2015; 56(10):2923-30. PubMed ID: 25629992
[TBL] [Abstract][Full Text] [Related]
31. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
32. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
33. Matrine increases NKG2D ligand ULBP2 in K562 cells via inhibiting JAK/STAT3 pathway: a potential mechanism underlying the immunotherapy of matrine in leukemia.
Lu X; Zhu Z; Jiang L; Sun X; Jia Z; Qian S; Li J; Ma L
Am J Transl Res; 2015; 7(10):1838-49. PubMed ID: 26692928
[TBL] [Abstract][Full Text] [Related]
34. Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.
Chen J; Lan T; Zhang W; Dong L; Kang N; Zhang S; Fu M; Liu B; Liu K; Zhan Q
Cancer Res; 2015 Oct; 75(19):4198-210. PubMed ID: 26359459
[TBL] [Abstract][Full Text] [Related]
35. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
Thress KS; Paweletz CP; Felip E; Cho BC; Stetson D; Dougherty B; Lai Z; Markovets A; Vivancos A; Kuang Y; Ercan D; Matthews SE; Cantarini M; Barrett JC; Jänne PA; Oxnard GR
Nat Med; 2015 Jun; 21(6):560-2. PubMed ID: 25939061
[TBL] [Abstract][Full Text] [Related]
36. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Zhang FQ; Yang WT; Duan SZ; Xia YC; Zhu RY; Chen YB
Oncotarget; 2015 Jun; 6(16):14329-43. PubMed ID: 25869210
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
